長療程糖皮質激素治療與急性呼吸窘迫綜合征_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

周秀芳 , 劉夢 ,  胡克

武漢大學人民醫院呼吸科(湖北武漢 430060);

Corresponding?author：

胡克, Email: huke-rmhospital@163.com

Keywords：

DOI：

10.7507/1671-6205.2014026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 周秀芳, 劉夢, 胡克. 長療程糖皮質激素治療與急性呼吸窘迫綜合征. Chinese Journal of Respiratory and Critical Care Medicine, 2014, 13(1): 101-104. doi: 10.7507/1671-6205.2014026 Copy

1.	Marik PE,Meduri GU,Rocco PR,et al. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin,2011,27:589-607.
2.	Meduri GU,Muthiah MP,Carratu P,et al. Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation,2005,12:321-338.
3.	Meduri GU,Headley S,Golden E,et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized controlled trial. JAMA,1998,280:159-165.
4.	Meduri GU,Tolley EA,Chrousos GP,et al. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome:evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med,2002,165:983-991.
5.	Meduri GU,Headley S,Tolley E,et al. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest,1995,108:1315-1325.
6.	Kellum JA,Kong L,Fink MP,et al. Understanding the inflammatory cytokine response in pneumonia and sepsis:results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med,2007,167:1655-1663.
7.	Lekkou A,Karakantza M,Mouzaki A,et al. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with communityacquired severe infections. Clin Diagn Lab Immunol,2004,11:161-167.
8.	Meduri GU,Marik PE,Chrousos GP,et al. Steroid treatment in ARDS:a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med,2008,34:61-69.
9.	Steinberg KP,Hudson LD,Goodman RB,et al. The Acute Respiratory Distress Syndrome Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med,2006,354:1671-1684.
10.	Meduri GU,Golden E,Freire AX,et al. Methylprednisolone infusion in patients with early severe ARDS:results of a randomized trial. Chest,2007,131:954-963.
11.	Meduri GU,Yates CR. Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Ann N Y Acad Sci,2004,1024:24-53.
12.	Henzen C,Suter A,Lerch E,et al. Suppression and recovery of adrenal response after short-term high-dose glucocorticoid treatment. Lancet,2000,355:542-545.
13.	Roquilly A,Mahe PJ,Seguin P,et al. Hydrocortisone therapy for corticosteroid insufficiency related to trauma. The HYPOLYT study. JAMA,2011,305:1201-1209.
14.	London L,Majeski EI,Altman-Hamamdzic S,et al. Respiratory reovirus 1/L induction of diffuse alveolar damage:pulmonary fibrosis is not modulated by corticosteroids in acute respiratory distress syndrome in mice. Clin Immunol,2002,103:284-295.
15.	Kehrer JP,Klein-Szanto AJ,Sorensen EM,et al. Enhanced acute lung damage following corticosteroid treatment. Am Rev Respir Dis,1984,130:256-261.
16.	Hakkinen PJ,Schmoyer RL,Witschi HP. Potentiation of butylatedhydroxytoluene-induced acute lung damage by oxygen. Effects of prednisolone and indomethacin. Am Rev Respir Dis,1983,128:648-651.
17.	Silva PL,Garcia CS,Maronas PA,et al. Early short-term versus prolonged low dose methylprednisolone therapy in acute lung injury. Eur Respir J,2009,33:634-645.
18.	Cerfolio RJ,Bryant AS,Thurber JS,et al. Intraoperative solumedrol helps prevent postpneumonectomy pulmonary edema. Ann Thorac Surg,2003,76:1029-1033.
19.	Confalonieri M,Urbino R,Potena A,et al. Hydrocortisone infusion for severe community-acquired pneumonia:a preliminary randomized study. Am J Respir Crit Care Med,2005,171:242-248.
20.	Tang BM,Craig JC,Eslick GD,et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome:a systematic review and meta-analysis. Crit Care Med,2009,37:1595-1603.
21.	Meduri GU,Annane D,Chrousos G,et al. Activation and regulation of systemic inflammation in ARDS. Rationale for prolonged glucocorticoid therapy. Chest,2009,136:1631-1644.
22.	Marik PE,Pastores SM,Annane D,et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients:consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med,2008,36:1937-1949.
23.	Annane D,Bellissant E,Bollaert P,et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults:a systematic review. JAMA,2009,301:2349-2361.
24.	Kaufmann I,Briegel J,Schliephake F,et al. Stress doses of hydrocortisone in septic shock:beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med,2008,34:344-349.
25.	Stevens RD,DowdyDW,Michaels RK,et al. Neuromuscular dysfunction acquired in critical illness:a systematic review. Intensive Care Med,2007,33:1876-1891.
26.	Hough CL,Steinberg KP,Taylor Thompson B,et al. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med,2009,35:63-68.
27.	Leatherman JW,Fluegle WL,David WS,et al. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med,1996,153:1686-1690.
28.	Weber-Carstens S,Deja M,Bercker S,et al. Impact of bolus application of low dose hydrocortisone on glycemic control in septic shock patients. Intensive Care Med,2007,33:730-733.
29.	Ceriello A,Esposito K,Piconi L,et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes,2008,57:1349-1354.
30.	Broug-Holub E,Kraal G. Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin Exp Immunol,1996,104:332-336.
31.	Fantuzzi G,Demitri MT,Ghezzi P. Differential effect of glucocorticoids on tumour necrosis factor production in mice:up-regulation by early pretreatment with dexamethasone. Clin Exp Immunol,1994,96:166-169.
32.	Barber AE,Coyle SM,Marano MA,et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol,1993,150:1999-2006.
33.	Loisa P,Parviainen I,Tenhunen J,et al. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock:a prospective randomized trial. Crit Care,2007,11:R21.
34.	Weber-Carstens S,Keh D. Bolus or continuous hydrocortisone-that is the question. Crit Care,2007,11:113.
35.	Cuthbertson BH,Sprung CL,Annane D,et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med,2009,35:1868-1876.

1. Marik PE,Meduri GU,Rocco PR,et al. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin,2011,27:589-607.
2. Meduri GU,Muthiah MP,Carratu P,et al. Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation,2005,12:321-338.
3. Meduri GU,Headley S,Golden E,et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized controlled trial. JAMA,1998,280:159-165.
4. Meduri GU,Tolley EA,Chrousos GP,et al. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome:evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med,2002,165:983-991.
5. Meduri GU,Headley S,Tolley E,et al. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest,1995,108:1315-1325.
6. Kellum JA,Kong L,Fink MP,et al. Understanding the inflammatory cytokine response in pneumonia and sepsis:results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med,2007,167:1655-1663.
7. Lekkou A,Karakantza M,Mouzaki A,et al. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with communityacquired severe infections. Clin Diagn Lab Immunol,2004,11:161-167.
8. Meduri GU,Marik PE,Chrousos GP,et al. Steroid treatment in ARDS:a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med,2008,34:61-69.
9. Steinberg KP,Hudson LD,Goodman RB,et al. The Acute Respiratory Distress Syndrome Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med,2006,354:1671-1684.
10. Meduri GU,Golden E,Freire AX,et al. Methylprednisolone infusion in patients with early severe ARDS:results of a randomized trial. Chest,2007,131:954-963.
11. Meduri GU,Yates CR. Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Ann N Y Acad Sci,2004,1024:24-53.
12. Henzen C,Suter A,Lerch E,et al. Suppression and recovery of adrenal response after short-term high-dose glucocorticoid treatment. Lancet,2000,355:542-545.
13. Roquilly A,Mahe PJ,Seguin P,et al. Hydrocortisone therapy for corticosteroid insufficiency related to trauma. The HYPOLYT study. JAMA,2011,305:1201-1209.
14. London L,Majeski EI,Altman-Hamamdzic S,et al. Respiratory reovirus 1/L induction of diffuse alveolar damage:pulmonary fibrosis is not modulated by corticosteroids in acute respiratory distress syndrome in mice. Clin Immunol,2002,103:284-295.
15. Kehrer JP,Klein-Szanto AJ,Sorensen EM,et al. Enhanced acute lung damage following corticosteroid treatment. Am Rev Respir Dis,1984,130:256-261.
16. Hakkinen PJ,Schmoyer RL,Witschi HP. Potentiation of butylatedhydroxytoluene-induced acute lung damage by oxygen. Effects of prednisolone and indomethacin. Am Rev Respir Dis,1983,128:648-651.
17. Silva PL,Garcia CS,Maronas PA,et al. Early short-term versus prolonged low dose methylprednisolone therapy in acute lung injury. Eur Respir J,2009,33:634-645.
18. Cerfolio RJ,Bryant AS,Thurber JS,et al. Intraoperative solumedrol helps prevent postpneumonectomy pulmonary edema. Ann Thorac Surg,2003,76:1029-1033.
19. Confalonieri M,Urbino R,Potena A,et al. Hydrocortisone infusion for severe community-acquired pneumonia:a preliminary randomized study. Am J Respir Crit Care Med,2005,171:242-248.
20. Tang BM,Craig JC,Eslick GD,et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome:a systematic review and meta-analysis. Crit Care Med,2009,37:1595-1603.
21. Meduri GU,Annane D,Chrousos G,et al. Activation and regulation of systemic inflammation in ARDS. Rationale for prolonged glucocorticoid therapy. Chest,2009,136:1631-1644.
22. Marik PE,Pastores SM,Annane D,et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients:consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med,2008,36:1937-1949.
23. Annane D,Bellissant E,Bollaert P,et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults:a systematic review. JAMA,2009,301:2349-2361.
24. Kaufmann I,Briegel J,Schliephake F,et al. Stress doses of hydrocortisone in septic shock:beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med,2008,34:344-349.
25. Stevens RD,DowdyDW,Michaels RK,et al. Neuromuscular dysfunction acquired in critical illness:a systematic review. Intensive Care Med,2007,33:1876-1891.
26. Hough CL,Steinberg KP,Taylor Thompson B,et al. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med,2009,35:63-68.
27. Leatherman JW,Fluegle WL,David WS,et al. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med,1996,153:1686-1690.
28. Weber-Carstens S,Deja M,Bercker S,et al. Impact of bolus application of low dose hydrocortisone on glycemic control in septic shock patients. Intensive Care Med,2007,33:730-733.
29. Ceriello A,Esposito K,Piconi L,et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes,2008,57:1349-1354.
30. Broug-Holub E,Kraal G. Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin Exp Immunol,1996,104:332-336.
31. Fantuzzi G,Demitri MT,Ghezzi P. Differential effect of glucocorticoids on tumour necrosis factor production in mice:up-regulation by early pretreatment with dexamethasone. Clin Exp Immunol,1994,96:166-169.
32. Barber AE,Coyle SM,Marano MA,et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol,1993,150:1999-2006.
33. Loisa P,Parviainen I,Tenhunen J,et al. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock:a prospective randomized trial. Crit Care,2007,11:R21.
34. Weber-Carstens S,Keh D. Bolus or continuous hydrocortisone-that is the question. Crit Care,2007,11:113.
35. Cuthbertson BH,Sprung CL,Annane D,et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med,2009,35:1868-1876.

Chinese Journal of Respiratory and Critical Care Medicine

長療程糖皮質激素治療與急性呼吸窘迫綜合征

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content